Amy D. Rix, Interim CEO, FounderAmy D. Rix, Interim CEO, Founder

Stop the Bleed with… NONOseseBLEEDBLEED …

Inc.

Problems that can be associated with frequent nosebleeds:

o Embarrassing especially when out in publico Loss of dignityo Loss of clotheso Having to stop what you are doingo Loss of time in a game (sports)

2

Social/Public Issues…Social/Public Issues…

Benefits of NOseBLEED•Is non-invasive to the nose•Does not restrict normal breathing•Stops nosebleeds in ~1-2 minutes•Product is digestible

TechnologyTechnologyTechnology Technology

Solution: Stop the bleed Solution: Stop the bleed with…with…

Technology

Market

• 2003 Study – 440 million total US nosebleeds per yearo Benninger and Marple - medical study (published/peer reviewed)

• 2008 Market Research Study- 700 million recurrent (more than 1 per month)

nosebleeds per yearo Leading online survey company

Sizable NeedSizable Need

Market

• Contract Manufacturing• Joint-venture distributors

―Cardinal Health―McKesson

• Direct sales model―Breathe Right Strips (CNS Inc.)―DURABOND (Closure Medical Corp.)

Partner and Exit OptionsPartner and Exit Options• CPC Licensing/Acquisition Options

―Johnson & Johnson (Closure Medical Corp., DURABOND)―GSK

• Medical Supply Licensing/Acquisition Options ―McKesson―Cardinal Health

Business

Business Model/ExitBusiness Model/Exit

Business

Financials

Financial ReturnFinancial ReturnYear 1 2 3 4 5

($ Millions)

Market Size* $648.0 $673.9 $700.9 $1,403.8 $1,460.0 Market Penetration** 3% 6% 9% 12% 15%

Revenue $19.4 $40.4 $63.1 $168.4 $219.0

Gross Margin $6.6 $13.7 $21.4 $57.3 $74.5 % of Revenue 34% 34% 34% 34% 34%

EBITDA $3.7 $8.8 $14.4 $44.8 $61.3 % of Revenue 18.9% 21.8% 22.8% 26.6% 28.0%

* Total Addressable Market (top 2 market segments yr 1-3, all segments yr 4-5)

** Source 2008 Market Study, Propensity to Buy Results = 18%

Milestones

Seed Round Milestones: • Regulatory opinions -

• Prototypes –

• Material selection –

• Market research –

• Segment strategy -

• FDA approval – Ongoing

• Manufacturing partner(s) – Ongoing

• Sterilization process – Ongoing

~$350K

Series A Milestones:Series A Milestones:

• $100 million revenue$100 million revenue

• Cash flow positiveCash flow positive

• Partner agreement and Partner agreement and exit exit

• IP ContinuationIP Continuation

$2.5 Million$2.5 Million

Value CreationValue Creation

Financials